Secondary Immunodeficiency (SID) in patients with haematological malignancies
Increasing incidence of SID caused by the underlying diseases and therapeutics.
Secondary immune deficiencies (SID) are caused by varied mechanisms and are common in patients with haematological malignancies such as chronic lymphocytic leukaemia (CLL) and multiple myeloma (MM). In addition, haematopoietic stem cell transplantation (HSCT) may be associated with secondary immunodeficiency.
Both the underlying disease and its treatment, e.g. B-cell targeting therapy, contribute to the development of secondary antibody deficiency. Infections remain a major cause of morbidity and mortality. Patients with severe and long-lasting disease are at greater risk.
As it has been shown for primary immunodeficiencies, studies indicate a clinical benefit of immunoglobulin therapy (IgG) as a treatment for secondary immunodeficiency. Thus, guidelines are in support of considering immunoglobulin replacement therapy in selected patients with secondary antibody deficiency.1
The importance of infection control in the management of haematological malignancies
Infection is a major complication in patients with haematological malignancies. Prophylaxis and infection control are key elements in the management of these patients
Prof. Isabella Quinti (Rome, Italy), Dr. Anne Quinquenel (Reims, France) and Prof. Igor-Wolfgang Blau (Berlin, Germany) share their perspective on the importance of secondary immune deficiencies and infections in patients with chronic lymphocytic leukaemia (CLL), multiple myeloma, lymphomas and stem cell transplant.
- 1. Patel, S. et al., S. Frontiers in Immunology 2019; 10: 33; Tadmor, T. et al, Expert Rev Hematol. 2018; 11 (1): 57-70; Benbrahim, O. et. al., Hematology 2018; 24(1): 173-182; Perez, E. et al., J Allergy Clin Immunol. 2017; 139:S1; Vacca, A. et al., Clinical Immunology 2017; 191: 110-115; EMA, Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) 2018.
- 2. Tadmor, T. et al., Expert Review of Hematology 2018; 11:1, 57-70; Hensel, M. et al., Eur J Haematol. 2017; 99(2):169-177; Da Cunha-Bang, C. et al., Blood Cancer J. 2016; 6(11).
- 3. Perez, E. et al., J Allergy Clin Immunol. 2017; 139:S1; Tomblyn, M. et al., Biol Blood Marrow Transplant. 2009; 15:1143; EMA, Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) 2018; Debes, A. et al., Pharmacoepidemiol Drug Saf. 2007; 16:1038; Raanani, P. et al., Leuk Lymphoma 2009; 50:764; Benbrahim, O. et al., Hematology 2018; 24(1):173-182.
- 4. Augustson, B.M. et al., J Clin Oncol. 2005; 23:9219-26; Teh, B.W. et al., Br J Haematol. 2015; 171:100-8; Blimark, C. et al., Haematologica. 2015; 100:107-13; Patel, S.Y. et al., Front Immunol. 2019; 10:33.
- 5. Ahn, H. et al., Transfusion 2018; 58: 2437-2452; Tomblyn, M. et al., Biol Blood Marrow Transplant. 2009; 15:1143.